Treating hepatitis C in the prison population is cost-saving.
D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D003363:Cost Control; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics* / Q000453:epidemiology / Q000401:mortality; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000191:economics / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000453:epidemiology / Q000209:etiology; D008390:Markov Chains; D008875:Middle Aged; D011092:Polyethylene Glycols; D015995:Prevalence; D011329:Prisoners / Q000706:statistics & numerical data*; D011994:Recombinant Proteins; D014481:United States / Q000453:epidemiology
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b